Professor | Zhejiang University School of Medicine | China
Dr. Xianguo Chen is an active researcher in the field of lung cancer biology, molecular oncology, and precision medicine, with a strong focus on exploring genetic alterations, therapeutic resistance mechanisms, and biomarker-driven clinical translation. Affiliated with the Zhejiang University School of Medicine, Dr. Chen has established a robust research portfolio, contributing 16 scientific publications, accumulating 48 citations, and maintaining an h-index of 4, reflecting consistent scholarly impact within a rapidly evolving biomedical landscape.Dr. Chen’s research spans critical areas of lung adenocarcinoma, non-small cell lung cancer (NSCLC), oncogenic signaling pathways, and clinical molecular diagnostics. His work includes multiple contributions as first author, corresponding author, and co-corresponding author, demonstrating scientific leadership and collaboration across multidisciplinary teams. Notable publications include studies on miR-1293–mediated angiogenesis regulation, carbonic anhydrase 4 as a prognostic biomarker, and the identification of novel RET and ALK fusions in NSCLC, each contributing valuable insights into cancer progression, heterogeneity, and precision-targeted therapy.His commitment to translational oncology is further reflected in several research grants. These include major funded projects focused on acacetin-mediated SMYD2 inhibition and DNA damage repair, KMT3C-driven osimertinib resistance via ENO1-regulated glycolysis, and metabolomic discrimination of pulmonary nodules combined with fecal microbiota transplantation strategies. These funded studies highlight his expertise in integrating molecular biology, bioinformatics, and therapeutic research to address pressing clinical challenges in cancer diagnosis and treatment.In addition to his publication record, Dr. Chen engages in collaborative research involving over 130 co-authors, demonstrating broad interdisciplinary partnerships across medical, molecular, and computational sciences. His recent article on machine learning–based immune prognosis modeling for lung adenocarcinoma extends his contributions into the domain of AI-assisted oncology, reinforcing the relevance of computational technologies in modern cancer research.Dr. Chen’s scientific efforts collectively aim to enhance early cancer detection, refine prognostic tools, and illuminate new molecular targets for therapy. Through his funded projects, high-quality publications, and sustained collaborative activity, he continues to contribute significantly to the advancement of global lung cancer research and its transition toward more personalized, mechanism-driven clinical care.
Featured Publication
1.Construction and validation of immune prognosis model for lung adenocarcinoma based on machine learning. (2025). Frontiers in Oncology.
Dr. Xianguo Chen research advances precision oncology by uncovering molecular mechanisms that drive lung cancer progression and therapeutic resistance, enabling more accurate diagnostics and targeted treatment strategies.